Sponsored Links

Kamis, 01 Februari 2018

Sponsored Links

Cutaneous T Cell Lymphoma - These welts are from cutaneous t ce...
src: lymphomapictures.org

Cutaneous T cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin lymphomas (which are generally B cell related), CTCL is caused by a mutation of T cells. The cancerous T cells in the body initially migrate to the skin, causing various lesions to appear. These lesions change shape as the disease progresses, typically beginning as what appears to be a rash which can be very itchy and eventually forming plaques and tumors before spreading to other parts of the body.


Video Cutaneous T cell lymphoma



Symptoms and signs

The presentation depends if it is mycosis fungoides or Sézary syndrome the most common, though not the only types. Among the symptoms for the aforementioned types are: lymphadenopathy, hepatosplenomegaly, and non-specific dermatitis.


Maps Cutaneous T cell lymphoma



Cause


ctcl
src: www.regionalderm.com


Diagnosis

A point-based algorithm for the diagnosis for early forms of cutaneous T cell lymphoma was proposed by The International Society for Cutaneous Lymphomas in 2005.

Classification

Cutaneous T-cell lymphoma may be divided into the several subtypes. Mycosis fungoides is the most common form of CTCL and is responsible for half of all cases.A WHO-EORTC classification has been developed.


Cutaneous T-Cell Lymphoma: Everything You Need to Know - YouTube
src: i.ytimg.com


Treatment

There is no cure for CTCL, but there are a variety of treatment options available and some CTCL patients are able to live normal lives with this cancer, although symptoms can be debilitating and painful, even in earlier stages. FDA approved treatments include the following:

  • (1999) Denileukin diftitox (Ontak)
  • (2000) Bexarotene (Targretin) a retinoid
  • (2006) Vorinostat (Zolinza) a hydroxymate histone deacetylase (HDAC) inhibitor
  • (2009) Romidepsin (Istodax) a cyclic peptide histone deacetylase (HDAC) inhibitor

Histone deacetylase (HDAC) inhibitors are shown to have antiproliferative and cytotoxic properties against CTCL.Other (off label) treatments include:

In 2010, the U.S. Food and Drug Administration granted orphan drug designation for a topical treatment for pruritus in cutaneous T-cell lymphoma to a pharmaceutical company called Elorac.


WHO-EORTC classification for cutaneous lymphomas | Blood Journal
src: www.bloodjournal.org


Epidemiology

Of all cancers involving the same class of blood cell, 2% of cases are cutaneous T cell lymphomas. CTCL is more common in men and in African-American people. The incidence of CTCL in men is 1.6 times higher than in women.

There is some evidence of a relationship with human T-lymphotropic virus (HTLV) with the adult T-cell leukemia/lymphoma subtype. No definitive link between any viral infection or environmental factor has been definitely shown with other CTCL subtypes.


CTCL, POIKILODERMATOUS
src: www.regionalderm.com


See also

  • Cutaneous B-cell lymphoma
  • List of cutaneous conditions

Recurrent cutaneous T cell lymphoma (mycosis fungoides) | Dermpedia
src: www.dermpedia.org


References


TNM classification system for primary cutaneous lymphomas other ...
src: www.bloodjournal.org


External links

  • DermNet dermal-infiltrative/cutaneous-t-cell-lymphoma


Source of the article : Wikipedia

Comments
0 Comments